GENFIT (GNFT.PA) Stock Price, Quote, News and Overview
EPA:GNFT - Euronext Paris - Matif - FR0004163111 - Common Stock - Currency: EUR
GNFT.PA Quote, Performance and Key Statistics
GENFIT
EPA:GNFT (2/4/2025, 7:00:00 PM)
3.64
+0.03 (+0.83%)
The current stock price of GNFT.PA is 3.64 EUR. In the past month the price increased by 2.82%. In the past year, price increased by 5.97%.
GNFT.PA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.57 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.87 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.72 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 919 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.86 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.76B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.7 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 7.04 | 1.45B |
Related stock screener links
About GNFT.PA
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 169 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE FR
Employees: 169
Company Website: https://www.genfit.fr/
Investor Relations: http://www.genfit.com/investors/financial-informations/
Phone: 33320164000
GNFT.PA FAQ
What is the stock price of GNFT.PA?
The current stock price of GNFT.PA is 3.64 EUR.
What is the symbol for GENFIT stock?
The exchange symbol of GENFIT is GNFT and it is listed on the Euronext Paris - Matif exchange.
On which exchange is GNFT.PA stock listed?
GNFT.PA stock is listed on the Euronext Paris - Matif exchange.
Is GNFT.PA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GNFT.PA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GNFT.PA.
Does GNFT.PA stock pay dividends?
GNFT.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of GNFT.PA?
The PE ratio for GNFT.PA is 9.84. This is based on the reported non-GAAP earnings per share of 0.37 and the current share price of 3.64 EUR.
GNFT.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GNFT.PA. When comparing the yearly performance of all stocks, GNFT.PA is a bad performer in the overall market: 87.41% of all stocks are doing better.
GNFT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GNFT.PA. Both the profitability and the financial health of GNFT.PA get a neutral evaluation. Nothing too spectacular is happening here.
GNFT.PA Financial Highlights
Over the last trailing twelve months GNFT.PA reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS increased by 153.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 26.51% | ||
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| Debt/Equity | 0.61 |
GNFT.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 91% to GNFT.PA. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 389.04% and a revenue growth 48.34% for GNFT.PA